Switch theme
Sign up to access all valuation multiples
CHO Pharma Inc is a biopharmaceutical company mainly focused on the development and commercialization of innovative products based on the proprietary glycan engineering technologies. It offers antibodies, such as CHO-H01, CHO-H02, CHO-A04 for cancer; CHO-H03, an antibody for autoimmune disease; CHO-S05 dual-effect anti-flu drugs; and CHO-V06 glycan-based vaccines and drugs.
2013
41
Last FY Revenue $0.1M
Last FY EBITDA -$6.2M
$208M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, CHO Pharma achieved revenue of $0.1M and an EBITDA of -$6.2M.
CHO Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CHO Pharma valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $0.1M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.1M | XXX | XXX | XXX |
| Gross Margin | XXX | 48% | XXX | XXX | XXX |
| EBITDA | XXX | -$6.2M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -5186% | XXX | XXX | XXX |
| EBIT | XXX | -$8.3M | XXX | XXX | XXX |
| EBIT Margin | XXX | -6963% | XXX | XXX | XXX |
| Net Profit | XXX | -$7.1M | XXX | XXX | XXX |
| Net Margin | XXX | -5928% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, CHO Pharma's stock price is TWD 40 (or $1).
CHO Pharma has current market cap of TWD 8.6B (or $286M), and EV of TWD 6.2B (or $208M).
See CHO Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $208M | $286M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, CHO Pharma has market cap of $286M and EV of $208M.
CHO Pharma's trades at 1744.4x EV/Revenue multiple, and -33.6x EV/EBITDA.
Equity research analysts estimate CHO Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CHO Pharma's P/E ratio is not available.
See valuation multiples for CHO Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $286M | XXX | $286M | XXX | XXX | XXX |
| EV (current) | $208M | XXX | $208M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 1744.4x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -33.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -25.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -40.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -28.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCHO Pharma's revenue per employee in the last FY averaged $3K, while opex per employee averaged $0.2M for the same period.
CHO Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CHO Pharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for CHO Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -5186% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $3K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 266% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6119% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 7011% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CHO Pharma acquired XXX companies to date.
Last acquisition by CHO Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . CHO Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was CHO Pharma founded? | CHO Pharma was founded in 2013. |
| Where is CHO Pharma headquartered? | CHO Pharma is headquartered in Taiwan. |
| How many employees does CHO Pharma have? | As of today, CHO Pharma has 41 employees. |
| Is CHO Pharma publicy listed? | Yes, CHO Pharma is a public company listed on ROCO. |
| What is the stock symbol of CHO Pharma? | CHO Pharma trades under 6586 ticker. |
| When did CHO Pharma go public? | CHO Pharma went public in 2017. |
| Who are competitors of CHO Pharma? | Similar companies to CHO Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of CHO Pharma? | CHO Pharma's current market cap is $286M |
| Is CHO Pharma profitable? | Yes, CHO Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
